Last reviewed · How we verify
NCT06985524
To Observe the Clinical Efficacy of Traditional Chinese Medicine Compound(Weipi Formula ) in the Treatment of Epigastric Stuffiness Syndrome
NA trial testing Weipi Formula（Wu SiSi Formula） in Functional Dyspepsia(FD) Was Studied in 256 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Second Affiliated Hospital of Nanchang University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 256 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Weipi Formula（Wu SiSi Formula） — full drug profile →
- Placebo
Conditions studied
- Functional Dyspepsia(FD) Was Studied — all drugs for Functional Dyspepsia(FD) Was Studied →
Sponsor
Second Affiliated Hospital of Nanchang University
Who can join
Adults 18 to 80, any sex, with Functional Dyspepsia(FD) Was Studied. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to evaluate the efficacy of the herbal drug Weipi formula in treating functional dyspepsia (FD) in adults. It will also assess the safety of Weipi formula. The main questions the study aims to answer are: Does Weipi formula reduce participants' TCM syndrome scores? What medical issues might participants experience while taking Weipi formula? Researchers will compare Weipi formula with a placebo (an identical-looking substance without active drugs) to determine whether Weipi formula is effective in treating functional dyspepsia. Participant Procedures Participants will: Take Weipi formula or the placebo daily for 2 weeks. Visit the clinic once every week for examinations and tests. Record their symptoms and undergo measurements (e.g., pepsin levels).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06985524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Second Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT07346794 — The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease · NA · not yet recruiting
- NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
- NCT07401784 — Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of I · NA · not yet recruiting
- NCT07290699 — Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period · Phase 4 · not yet recruiting
- NCT07295444 — A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mil · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06985524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Nanchang University
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06985524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing